

Overview of Gilead Sciences Scientific Presentations

HIV Prevention Research	
Presentation 392	Favorable Adherence and Safety of Twice-Yearly Subcutaneous Lenacapavir for PrEP Among PURPOSE 2 Participants Who Used Substances
Presentation 390	Lenacapavir Adherence and Effectiveness Over 2 Years of Use in the OPERA Cohort
P-299	No Clinically Significant Drug-Drug Interactions Between Lenacapavir and Hormonal Contraceptives in PURPOSE 1
P-305	No Clinically Significant Drug-Drug Interactions with Co-administration of Feminizing or Masculinizing Hormone Therapy and Twice-yearly Lenacapavir PrEP in Gender-Diverse Persons
P-382	PrEP Utilization Patterns and Indications in a Cohort of HIV-Negative Individuals
P-326	Barriers to Oral HIV Pre-Exposure Prophylaxis (PrEP) Perceived by Those Receiving an Initial Prescription: US Survey Analysis
P-287	Real-World Sexually Transmitted Infection (STI) Testing Patterns Among Individuals Using PrEP for HIV-1 Prevention in the United States
HIV Treatment Research	
P-357	Geographic Variations of HIV Specialist Shortages: An Observational Study to Support the 90-90-90 HIV Treatment Goals in the US
P-382	Characteristics and Outcomes of People with HIV (PWH) with Suboptimal Adherence on B/F/TAF or Dolutegravir Single-Tablet Regimens (STRs)
P-386	A Phase 4 Study to Evaluate the Safety and Efficacy of Oral B/F/TAF After Discontinuing Injectable CAB + RPV
P-387	Evaluation of Treatment Satisfaction and Experiences Among People With HIV When Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide From Cabotegravir + Rilpivirine: Results From the Phase 4 EMPOWER Study
P-390	Persistence and Adherence of PWH and Mental Health Disorder Diagnosis who Restart Antiretroviral Therapy (ART)
P-391	Impact of Rapid Antiretroviral Therapy Initiation on Retention in Care and Viral Suppression in an urban HIV clinic in Louisville, Kentucky
P-393	Treatment Switch among Medicare-insured People with HIV and Gaps in Care
P-394	Antiretroviral Therapy Persistence Following a Change or Restart in Regimen Among People with HIV
P-2034	Evaluation of Implementing Text-Messaging Based Medication Reminders to Improve Adherence to Antiretrovirals in People Living with HIV
P-2043	Improving Access and Adherence to Antiretroviral Therapy Through Coordinated Outreach and Care Linkage Model: A Collaborative Program Evaluation
P-2071	Reaching the Hard-to-Reach ACCELERATE Model of HIV Care: Telehealth, Rapid Restart, Follow-up
P-2084	HIV Viewpoints: Survey on the Experiences of People Living with HIV in North America
Respiratory, Hepatitis, and Pandemic Viruses	
P-1276	Remdesivir And Obeldesivir Retain Potent Activity Against SARS-CoV-2 Omicron Variants
P-1625	SARS-CoV-2 Viral Load Dynamics in Participants With Solid Organ Transplantation and Severely Reduced Kidney Function From the Remdesivir Phase 3 REDPINE Study Who Were Hospitalized for COVID-19
P-1632	Effectiveness of Remdesivir in Patients With Underlying Hepatic or Renal Comorbidity Hospitalized For SARS-CoV-2 Infection
P-661	Treatment Patterns Observed Among Immunocompromised and Frail Hospitalized COVID-19 Patients in the US
P-1232	Dose Selection of Obeldesivir for Clinical Evaluation in Treatment of Adult Participants with Respiratory Syncytial Virus Infection
P-1231	A Phase 1 Open-label, Parallel-group, Single-dose Study to Evaluate the Pharmacokinetics and Safety of Obeldesivir in Participants with Normal Renal Function and Renal Impairment

P-1169	Obeldesivir and GS-441524 Antiviral Activity against L Protein Mutants in Respiratory Syncytial Virus (RSV) Minigenome and Recombinant Infectious Virus Systems
P-686	Evolving Patterns Of Testing For Respiratory Syncytial Virus In The United States: Who Is Getting Tested?
P-1166	Obeldesivir Clinical Dose Projection for Marburg Virus Disease Post-Exposure Prophylaxis
P-2195	Influence of Nucleos(t)ide Analogue Use With Bulevirtide on Treatment Outcomes in Chronic Hepatitis Delta